Market Overview

Medpace Holdings, Inc. Announces Secondary Offering of Common Stock by Selling Shareholder

Share:

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced a
secondary offering of 5,224,997 shares of its common stock by investment
funds affiliated with Cinven Capital Management (V) General Partner
Limited (the "Selling Shareholder"). The offering consists entirely of
secondary shares of common stock to be sold by the Selling Shareholder.
Medpace will not receive any proceeds from the sale of the shares of
common stock by the Selling Shareholder.

Morgan Stanley is acting as the sole bookrunner for the offering. Morgan
Stanley proposes to offer the shares of our common stock from time to
time for sale in one or more transactions on the NASDAQ Global Select
Market, in the over-the-counter market, through negotiated transactions
or otherwise at market prices prevailing at the time of sale, at prices
related to such prevailing market prices or negotiated prices, subject
to their right to reject any order in whole or in part.

The offering will be made only by means of a prospectus supplement and
an accompanying prospectus. Copies of the prospectus supplement, when
available, and the accompanying prospectus relating to this offering may
be obtained by contacting Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York
10014.

A registration statement on Form S-3 (including a prospectus) relating
to the securities being sold in the offering has been declared effective
by the Securities and Exchange Commission. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
such state or jurisdiction.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical
contract research organization (CRO) providing Phase I-IV clinical
development services to the biotechnology, pharmaceutical and medical
device industries. Medpace's mission is to accelerate the global
development of safe and effective medical therapeutics through its
high-science and disciplined operating approach that leverages local
regulatory and deep therapeutic expertise across all major areas
including oncology, cardiology, metabolic disease, endocrinology,
central nervous system and anti-viral and anti-infective. Headquartered
in Cincinnati, Ohio, Medpace employs approximately 2,700 people across
36 countries.

View Comments and Join the Discussion!